Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.
While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years.
Exclusive: investigation finds prescriptions for children under 12, as experts stress need for specialist supervision and long-term monitoring Hundreds of children in England are receiving prescriptions for GLP-1 medications, including some younger than 12, the Guardian can reveal. GLP-1 medications were initially developed to help people with type 2 diabetes control their blood sugar levels, but have since become a popular slimming aid, with products such as Wegovy and…
The world’s first attempt to edit genes inside a child’s brain, which killed a six-year-old girl in Shanghai last year, has led to the firing of scientists following an official investigation that found they had broken research rules and taken money from her family. The investigation, ordered by the Communist Party’s Shanghai municipal committee and the local government, concluded on Friday that the researchers had not shared worrying results from monkey tests with the…
Researchers created a detailed map of the tumor microenvironment surrounding estrogen receptor-positive ductal carcinoma in situ, which may help better predict progression to invasive breast cancer and inform on future therapeutic strategies.
Oregon-based Araceli Biosciences raised $4.5 million to commercialize cell-imaging tools that help researchers test potential drugs using human cells, with the aim of reducing reliance on animal studies while producing more relevant results.
A genomic study reveals how genetic mutations, recombination, and resistance-carrying plasmids shaped the evolution, diversification, and decline of vancomycin-resistant Enterococcus faecium in Danish hospitals between 2012 and 2020.
In this GEN webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves.
The Trump administration will funnel up to $4.9 million into supporting research into ibogaine, a psychedelic that’s drawn interest as a potential treatment for PTSD and addiction.
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.
4 Mins ReadIndian biotech firm Symbiotec Pharmalabs has signed a 10-year deal to serve as a contract manufacturer for a European company’s precision-fermented protein. Shoring up India’s biomanufacturing prowess, Symbiotec Pharmalabs has expanded its contract manufacturing services for a European innovator in alternative proteins. The biotech firm has signed a 10-year take-or-pay agreement with an unnamed European
Is biotechnology becoming the next space race? The Biotechnology Innovation Organization (BIO) appears to think so. This month, it urged Washington to adopt a comprehensive national biotechnology strategy, warning that China is rapidly gaining ground in an industry now viewed as critical to economic competitiveness and national security. The United States and China have spent
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed as Foundayo, could be used for chronic weight management by obese or overweight adults. GLP-1 receptor agonists…
Using DNA sequenced from patient blood samples, researchers assembled complete reference genomes of neglected malaria parasites, uncovering genetic regions potentially involved in immune evasion and providing new tools for disease surveillance.
A study finds that everyone in a diverse, nearly 100,000-person sample carried at least one genetic variant that affects how their body processes medications, and a quarter of those people had been prescribed a medication that is known to be impacted by the variant they carried.
The blood-brain barrier keeps most proteins in the bloodstream out of the brain, but not all. The pathways that import them are damaged early in Alzheimer’s disease models, hinting at new ways to treat the disease.
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
Google Deepmind has unveiled AlphaGenome 2, an AI model that analyzes genetic variants for individual cell types rather than across bulk tissue. Trained on more than 107 million cell profiles, it identifies nearly twice as many disease-relevant gene changes as its predecessor. The model is available for noncommercial research through an API and is set to be integrated into Google's agentic platform Antigravity. The article Google Deepmind shifts genomics AI from bulk tissue…
A former ByteDance artificial intelligence scientist’s new venture has released a life sciences AI model that the firm claims outperforms state-of-the-art systems, intensifying the increasingly crowded competition in AI-driven drug discovery. Geodesic Intelligence’s NovaAtom-Lite, an AI model designed to predict the structures and interactions of biomolecules, topped a third-party benchmark in several drug discovery tasks, founder Quanquan Gu said on social media on…